Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Lee, Ann Sing
Zee, Benny C. Y.
Cheung, Foon Yiu
Kwong, Philip
Cheng, Ashley Chi Kin
Lai, Maria
Kwok, Chloe
Chong, Marc
Jolivet, Jacques
Chiang, C. L.
Leung, K. C.
Siu, Steven
Lee, Conrad
Tung, Stewart Yuk
机构：
[1] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[4] Queen Mary Hosp, North Point, Hong Kong, Peoples R China
[5] Princess Margaret Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Aegera Therapeut Pharmasci Inc, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Kowloon, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4105
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Lee, Francis A. S.
    Zee, Benny Chung-Ying
    Cheung, Foon Yiu
    Kwong, Philip
    Chiang, Chi Leung
    Leung, Kwong Chuen
    Siu, Steven W. K.
    Lee, Conrad
    Lai, Maria
    Kwok, Chloe
    Chong, Marc
    Jolivet, Jacques
    Tung, Steward
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06): : 609 - 613
  • [2] Phase I portion of the phase I-II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Lee, A. S.
    Zee, B. C.
    Lai, M.
    Jolivet, J.
    Wong, C. S.
    Chiang, C. L.
    Tong, M.
    Tung, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis
    LaCasse, Eric C.
    Cherton-Horvat, Gabriele G.
    Hewitt, Kimberley E.
    Jerome, Lori J.
    Morris, Stephen J.
    Kandimalla, Ekambar R.
    Yu, Dong
    Wang, Hui
    Wang, Wei
    Zhang, Ruiwen
    Agrawal, Sudhir
    Gillard, John W.
    Durkin, Jon P.
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5231 - 5241
  • [4] Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
    J Cummings
    M Ranson
    E LaCasse
    J R Ganganagari
    M St-Jean
    G Jayson
    J Durkin
    C Dive
    British Journal of Cancer, 2006, 95 : 42 - 48
  • [5] Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
    Cummings, J.
    Ranson, M.
    LaCasse, E.
    Ganganagari, J. R.
    St-Jean, M.
    Jayson, G.
    Durkin, J.
    Dive, C.
    BRITISH JOURNAL OF CANCER, 2006, 95 (01) : 42 - 48
  • [6] A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.
    Ranson, M.
    Dive, C.
    Ward, T.
    Cummings, J.
    Connolly, K.
    Evans, S.
    Robson, L.
    Durkin, J.
    Jolivet, J.
    Jodrell, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 135S - 135S
  • [7] Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
    Schimmer, Aaron D.
    Estey, Elihu H.
    Borthakur, Gautam
    Carter, Bing Z.
    Schiller, Gary J.
    Tallman, Martin S.
    Altman, Jessica K.
    Karp, Judith E.
    Kassis, Jeannine
    Hedley, David W.
    Brandwein, Joseph
    Xu, Wei
    Mak, Duncan H.
    LaCasse, Eric
    Jacob, Christine
    Morris, Stephen J.
    Jolivet, Jacques
    Andreeff, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4741 - 4746
  • [8] Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
    Cummings, J
    Ward, TH
    LaCasse, E
    Lefebvre, C
    St-Jean, M
    Durkin, J
    Ranson, M
    Dive, C
    BRITISH JOURNAL OF CANCER, 2005, 92 (03) : 532 - 538
  • [9] Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
    J Cummings
    T H Ward
    E LaCasse
    C Lefebvre
    M St-Jean
    J Durkin
    M Ranson
    C Dive
    British Journal of Cancer, 2005, 92 : 532 - 538
  • [10] Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML
    Schimmer, Aaron D.
    Estey, Elihu H.
    Borthakur, Gautam
    Carter, Bing
    Schiller, Gary J.
    Tallman, Martin S.
    Altman, Jessica K.
    Karp, Judith E.
    Kassis, Jeannine
    Jacob, Christine
    Morris, Stephen
    Jolivet, Jacques
    Andreeff, Michael
    BLOOD, 2008, 112 (11) : 283 - 284
12345